| |
N = 11
|
|---|
|
Age at Tx (years)a
|
65.4 (47–75)
|
|
Gender (male)
|
8 (72.7%)
|
|
Years between Tx and first cSCCa
|
2.6 (1.1–11.5)
|
|
Years between Tx and post-Tx samplea
|
2.1 (0.3–13.0)
|
|
CMV acceptor
|
|
Negative
|
4 (36.4%)
|
|
Positive
|
7 (63.6%)
|
|
CMV donor
|
|
Negative
|
7 (63.6%)
|
|
Positive
|
4 (36.4%)
|
|
HLA mismatchesa
|
2 (0–6)
|
|
Type of immunosuppression directly after transplantation
|
|
Corticosteroids
|
10 (90.9%)
|
|
Tacrolimus
|
10 (90.9%)
|
|
MMF
|
10 (90.9%)
|
|
Cyclosporine
|
1 (9.1%)
|
|
Sirolimus
|
1 (9.1%)
|
|
Basiliximab induction
|
3 (27.3%)
|
|
ATG induction
|
1 (9.1%)
|
|
ESRD diagnosis
|
|
Polycystic kidney
|
5 (45.5%)
|
|
Hypertension
|
1 (9.1%)
|
|
Other
|
5 (45.5%)
|
|
Dialysis pre-transplantation
|
|
Yes
|
8 (72.7%)
|
|
No
|
3 (27.3%)
|
- aMedian and range
- cSCC cutaneous squamous cell carcinoma, CMV cytomegalovirus, ESDR end-stage renal disease
